The University of Chicago Header Logo

Connection

Daniel J. Haraf to Angiogenesis Inhibitors

Back to Details
This is a "connection" page, showing publications Daniel J. Haraf has written about Angiogenesis Inhibitors.
Daniel J. Haraf
Connection Strength
0.017
Angiogenesis Inhibitors
  1. Phase I study of bevacizumab added to fluorouracil- and hydroxyurea-based concomitant chemoradiotherapy for poor-prognosis head and neck cancer. J Clin Oncol. 2008 Apr 01; 26(10):1732-41.
    View in: PubMed
    Score: 0.017
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.